scholarly journals Panel of genetic markers for predicting the risk of developing dry eye disease of various etiologies

2021 ◽  
pp. 366-373
Author(s):  
T. N. Safonova ◽  
G. V. Zaitseva ◽  
A. M. Burdennyy ◽  
V. I. Loginov
Keyword(s):  
Genetic Markers ◽  
Dry Eye ◽  
Melting Curve ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Melting Curve Analysis ◽  
Control Group ◽  
Polymorphic Markers ◽  
Expression Of Genes ◽  
Diagnostic Panel

Introduction. World statistics indicate an increase in patients, including young people, suffering from dry eye disease (DED). Along with exogenous factors, the development of DED depends on a genetic predisposition. Changes in the expression of genes PTPN22, TRIM21, directly or indirectly affecting the T-cell link of immunity, leads to overproduction of cytokines and, as a consequence, damage to the ocular surface.This study aimed to design a diagnostic panel of genetic markers to determine the risk for DED of various etiologies development.Materials and methods. The  study included 154  patients with autoimmune diseases with and without established DED. With a  diagnosis of  rheumatoid arthritis (RA) n  =  79  and primary Sjogren’s syndrome (PSS) n  =  75. The  control group consisted of 100 people without ophthalmic diseases, 31 patients with exogenous DED. In this study, we use melting curve analysis to confirm the results of the association analysis for polymorphic markers in genes.Results. The prognostic value of the predisposing genotypes of the TRIM21 gene of the markers rs915956 and rs7947461 with the risk of DED in the presence of RA (p ≤ 0.001), the marker rs4144331 at the tendency level (p ≤ 0.1) was determined. The risk of developing DES against the  background of  PSS is associated with the  presence of  the  predisposing genotypes of  the  TRIM21  genes, the rs4144331 marker, and the PTPN22 rs33996649 marker (p ≤ 0.001). The association of polymorphic markers of the TRIM21 rs7947461 gene and the PTPN22 gene of the rs33996649 marker (p ≤ 0.01) with the risk of developing exogenous DED was established.Conclusions. The predisposing genotypes were identified and the associations of polymorphic markers of the TRIM21, PTPN22 genes were established. A diagnostic panel of genetic markers has been created to predict DED of various etiologies. 

scholarly journals The Development of Dry Eye Disease after Surgery-Indicated Chronic Rhinosinusitis: A Population-Based Cohort Study

2020 ◽  
Vol 17 (11) ◽  
pp. 3829
Author(s):  
Chia-Yi Lee ◽  
Kun-Lin Yang ◽  
Chi-Chin Sun ◽  
Jing-Yang Huang ◽  
Hung-Chih Chen ◽  
...  
Keyword(s):  
Chronic Rhinosinusitis ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Sinus Surgery ◽  
Eye Disease ◽  
Cumulative Probability ◽  
Control Group ◽  
Study Group ◽  
Diagnostic Code ◽  
Research Database

We aim to evaluate the risk of dry eye disease (DED) occurrence in patients with surgery-indicated chronic rhinosinusitis (CRS) via the national health insurance research database in Taiwan. After exclusion, patients with a diagnostic code of CRS and had received functional endoscopic sinus surgery (FESS) were regarded as having surgery-indicated CRS and enrolled in the study group, then each patient in the study group was age- and gender-matched to four non-CRS patients that served as the control group. The outcome was considered as the development of DED and Cox proportional hazard regression was used for the statistical analysis, which involved multiple potential risk factors of DED. A total of 6076 patients with surgery-indicated CRS that received FESS and another 24,304 non-CRS individuals were enrolled after exclusion. There were 317 and 770 DED events in the study group and the control group during the 16-year follow-up interval, and the study group demonstrated a significantly higher adjusted hazard ratio (1490, 95% confidence intervals (CI): 1.303-1.702) of DED development compared to the control group in the multivariable analysis. In addition, the cumulative probability analysis illustrated a positive correlation of DED occurrence and the disease period of surgery-indicated CRS (p < 0.0001). In the subgroup analysis, both genders revealed a higher but not significant incidence of developing DED in the study group. In conclusion, the existence of surgery-indicated CRS will increase the risk of developing DED, which correlated to the disease interval.

scholarly journals Apigenin ameliorates ocular surface lesions in a rat model of dry eye disease

2019 ◽  
Vol 17 ◽  
pp. 205873921881868
Author(s):  
Limei Liu ◽  
Dongdong Wei ◽  
Hongkun Xu ◽  
Changhui Liu
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Histopathological Examination ◽  
Tear Film ◽  
Interleukin 10 ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Necrosis Factor Alpha

To study the effects of apigenin on dry eye disease (DED) in rats. Rats were divided into six groups: (I) normal control group, (II) DED control group, (III) vehicle control group, (IV) DED + apigenin 10 mg/kg, (V) DED + apigenin 20 mg/kg, and (VI) DED + apigenin 50 mg/kg. Schirmer test, tear film break-up time (BUT), and corneal fluorescein staining were used to evaluate the effects of apigenin on the ocular surface. The related inflammatory cytokines were detected by enzyme-linked immunosorbent assay (ELISA). Histopathological examination and inflammatory index were also performed. The results showed that administration of apigenin was shown a significant effect on the recovery of ocular surface function. Compared to the control group, apigenin treatment in DED rats significantly decreased the level of the tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6); however, the interleukin-10 (IL-10) level was increased. Histopathological examination further verified the anti-inflammatory effects of apigenin on DED rats. The results demonstrated that apigenin could protect DED rats via inhibition of inflammation, suggesting that it may have potential as a therapy for DED.

New model to better diagnose dry eye disease integrating OCT corneal epithelial mapping

2021 ◽  
pp. bjophthalmol-2021-318826
Author(s):  
Norah A Edorh ◽  
Adil El Maftouhi ◽  
Zoubir Djerada ◽  
Carl Arndt ◽  
Alexandre Denoyer
Keyword(s):  
Dry Eye ◽  
Roc Curves ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Control Group ◽  
Scoring Method ◽  
Corneal Epithelial ◽  
Epithelial Thickness ◽  
Final Multivariable Model ◽  
The Difference

PurposeTo optimise the objective diagnosis of dry eye disease (DED), the capabilities of wide corneal epithelial mapping using optical coherence tomography (OCT) were studied and subsequently integrated into a new scoring method.MethodsFifty-nine patients (118 eyes) with DED and 55 control subjects (110 eyes) were included. All patients underwent a complete ocular surface evaluation. Corneal epithelial thickness was collected using OCT for seven zones. DED and the control group were compared using a t-test, and univariate receiver operating characteristic (ROC) curves were calculated to define the diagnostic ability of OCT epithelial mapping. Multivariate analyses were performed using artificial intelligence (random forest) and logistic regression approaches to define the best way to integrate OCT mapping in the diagnosis of DED. Then, a final multivariable model for diagnosing DED was validated through a bootstrapping method.ResultsThe DED group had significant epithelial thinning compared with the controls, regardless of location. Superior intermediate epithelial thickness was the best marker for diagnosing DED using OCT (binormal estimated area under ROC: 0.87; best cut-off value: 50 µm thickness). The difference between the inferior and superior peripheral zones was the best marker for grading the severity of DED (analysis of variance, p=0.009). A multivariate approach identified other significant covariables which were integrated into a multivariate model to improve the sensitivity (86.4%) and specificity (91.7%) of this innovative diagnostic method.ConclusionIncluding OCT corneal epithelial mapping in a new diagnostic tool for DED could allow optimisation of the screening and staging of the disease in current practice as well as for clinical research purposes.

scholarly journals Gout as a Risk Factor for Dry Eye Disease: A Population-Based Cohort Study

2019 ◽  
Vol 8 (1) ◽  
pp. 62 ◽  
Author(s):  
Chia-Yi Lee ◽  
Hung-Chi Chen ◽  
Chi-Chin Sun ◽  
Hung-Yu Lin ◽  
Ko-Hsiu Lu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Age Related Macular Degeneration ◽  
Eye Disease ◽  
Cumulative Probability ◽  
Control Group ◽  
Study Group ◽  
Research Database ◽  
Increased Risk

This study evaluated the effect of gout on the risk of dry eye disease (DED) by using the National Health Insurance Research Database (NHIRD). Data for 30,192 gout patients (21,081 men and 9111 women) and 30,192 non-gout patients (21,005 men and 9187 women) were analyzed. Approximately 1 million patients were randomly sampled from the NHIRD registry. After applying exclusion criteria, patients diagnosed with gout were enrolled in the study group. Thereafter, each individual in the study group underwent the matching process via the propensity score with another non-gout individual, which constituted the control group. The main outcome was defined as the development of DED in accordance with the corresponding International Classification of Diseases, Ninth Revision. In addition to DED, other risk factors including age, sex, and urbanization, and several co-morbidities were included in the multivariate model. The incidence of DED with the adjusted hazard ratio (aHR) and cumulative probability were evaluated in the gout and non-gout patients. A total of 2913 DED events were observed in the study group, whereas 2631 DED events were observed in the control group. A higher incidence rate ratio was found in the study group after adjustment (aHR: 1.065). Moreover, the cumulative probability indicated a significantly increased risk of DED in the study group (p = 0.001). The other potential risk factors of DED according to the multivariate analysis include older age, female gender, higher degree of urbanization, keratopathy, age-related macular degeneration, glaucoma, cataract, ischemic heart disease, hyperlipidemia, peripheral vascular disease, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, liver disease, and malignancy. In conclusion, gout increased the risk of DED after adjustment, and the risk is positively correlated to a longer disease period.

scholarly journals TO EVALUATE THE EFFECT OF TOPICAL 2% REBAMIPIDE OPHTHALMIC SUSPENSION IN PATIENTS WITH DRY EYE DISEASE.

2021 ◽  
Vol 5 (8) ◽  
Author(s):  
Shakti Krishan Rajguru ◽  
Udesh Rajpurohit
Keyword(s):  
Dry Eye ◽  
Ophthalmic Solution ◽  
Public Health Problem ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Control Group ◽  
P Value ◽  
Chi Square ◽  
Chi Square Test ◽  
Ophthalmic Suspension

Background: Dry eye is an important public health problem causing ocular discomfort, fatigue and visual disturbance that may interfere with daily activities Methods: It is a prospective, randomized, analytical hospital based study. Minimum Sample size of 80 patients which is randomly allocated in the study (cases) and control group.  In the study group topical 2% rebapimide ophthalmic suspension and in control group 0.5% caboxymethyl cellulose ophthalmic solution were given after comprehensive ophthalmic evaluation. Results: In mild OSDI score chi square test showed p value as 0.07 which was statistically not significant. In moderate OSDI score chi square test showed p value as 0.07 which was statistically not significant.  In severe OSDI score chi square test showed p value as 0.04 which was statistically significant. Conclusion: Rebamipide 2% ophthalmic suspension is an effective treatment in dry eye disease due to mucin deficiency. There was significant improvement in signs and symptoms of dry eye Keywords: OSDI, Dry eye, Rebamipide 2% ophthalmic suspension

scholarly journals Topical Instillation of Resveratrol Preconditioned Wharton’s Jelly Mesenchymal Stem Cell Secretome Preserves Ocular Surface in Experimental Model of Severe Dry Eye Disease

2020 ◽  
Vol 8 (B) ◽  
pp. 1116-1123
Author(s):  
Diandra Astaridewi ◽  
Evelyn Komaratih ◽  
Yuyun Rindiastuti ◽  
Yohanes Widodo Wirohadidjojo ◽  
Djoko Legowo ◽  
...  
Keyword(s):  
Experimental Model ◽  
Dry Eye ◽  
Goblet Cell ◽  
Ocular Surface ◽  
Inflammatory Cells ◽  
Dry Eye Disease ◽  
Wharton’S Jelly ◽  
Eye Disease ◽  
Control Group ◽  
Wharton's Jelly

BACKGROUND: Secretome derived from Wharton’s jelly mesenchymal stem cells (WJ-MSC) has a beneficial effect for ocular surface regeneration; however, the high amount of vascular endothelial growth factor (VEGF) remains a challenge for its application. AIM: The aim of the study was to investigate the effect of resveratrol (RV) (VEGF reducing agent) preconditioned WJ-MSC secretome in Concanavalin A-induced severe dry eye model. METHODS: Pre- and post-experimental study composed of topical instillation of WJ-MSC secretome group, balanced salt solution control group, and normal control group. Tear production, tear break-up time (TBUT), corneal fluorescein dye staining, VEGF level in aqueous tear, goblet cell density, and inflammatory cells in the ocular surface were analyzed. RESULTS: Topical instillation of RV preconditioned WJ-MSC secretome successfully improved tear film production (p = 0.008) and TBUT (p = 0.008), promoted goblet cell restoration (p = 0.023) and reduced corneal fluorescein staining (p = 0.003), while inhibited infiltration of inflammatory cells (p = 0.01) and secretion of VEGF in aqueous tear (p = 0.003). CONCLUSION: Topical instillation of RV preconditioned WJ-MSC secretome has great potential as cell-free based therapy to preserve ocular surface in an experimental model of severe Dry eye disease.

scholarly journals Meibomian Gland dysfunction and dry eye disease symptoms in patients with type 2 Diabetes Mellitus

2019 ◽  
Vol 25 (4) ◽  
pp. 51-55
Author(s):  
Т.М. Zhmud ◽  
N.V. Malachkova ◽  
O.O. Andrushkova ◽  
К.Y. Hrizhymalska
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Dry Eye ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Control Group ◽  
Patients With Diabetes ◽  
Meibomian Glands

An important problem to date is the dysfunction of meibomian glands in patients with type 2 diabetes. The aim of our work was to analyze the prevalence of meibomian gland dysfunction and signs of dry eye disease in patients with type 2 diabetes. We examined 40 patients (80 eyes) with compensated type 2 diabetes mellitus and symptoms of dry eye disease, who made up the main group at the age of 54.00±8.00 years, and 30 patients (60 eyes) of practically healthy people, aged 51.00±8.00 years. All patients underwent visiometry, biomicroscopy, ophthalmoscopy, tonometry, compression test to evaluate the secretion of meibomian glands, Schirmer’s test for compression before and after 30 min. Afterwards, Norn test, meibography, Demodex mite test, laboratory tests (lipidogram, blood glucose, glycosylated hemoglobin). In addition, standard OSDI, McMonnies Dry Eye Questionnaire questionnaires were used and an average clipping rate of1 min was determined. Statistical processing of the obtained results was carried out using the license package “Statistica 8.0” using parametric estimation methods. Our study has shown that in patients with diabetes for more than 5 years, dry eye disease occurs more often and is dominated by moderate and severe severity. Each patient in the study group, together with the symptoms of dry eye, had signs of dysfunction of the meibomian glands of varying degrees of severity according to the compression test and objective symptoms of the disease. A significant difference was found between the clipping frequency in the control group and the main one (p≤0.01). Compared with the control group, patients with diabetes have a longer interval between the clipping movements. Meibography data show that patients in the primary group have changes in the meibomian glands in 90% of cases, while in the control group – 44%. Thus, it was found that patients with type 2 diabetes had dysfunction of meibomian glands of moderate severity in 90% of cases, which is associated with the duration of diabetes.

scholarly journals The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial

2020 ◽  
Vol 9 (11) ◽  
pp. 3536 ◽  
Author(s):  
Gysbert-Botho van Setten ◽  
Christophe Baudouin ◽  
Jutta Horwath-Winter ◽  
Daniel Böhringer ◽  
Oliver Stachs ◽  
...  
Keyword(s):  
Molecular Weight ◽  
High Molecular Weight ◽  
Dry Eye ◽  
Tear Film ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Control Group ◽  
Eye Drops ◽  
Artificial Tears ◽  
Ocular Surface Disease Index

The aim of the HYLAN M study was to investigate if symptoms and/or signs of patients suffering from severe dry eye disease (DED) can be improved by substituting individually optimized artificial tear therapy by high molecular weight hyaluronan (HMWHA) eye drops. In this international, multicenter study, patients with symptoms of at least ocular surface disease index (OSDI) 33 and corneal fluorescein staining (CFS) of at least Oxford grade 3 were included. A total of 84 per-protocol patients were randomized in two study arms. The control group continued to use their individual optimum artificial tears over the study period of eight weeks; in the verum group, the artificial tears were substituted by eye drops containing 0.15% HMWHA. At the week 8 visit, the average OSDI of the verum group had improved by 13.5 as compared to the control group (p = 0.001). The best corrected visual acuity (BCVA) had improved by 0.04 logMAR (p = 0.033). CFS, tear film break-up time (TBUT), Schirmer I, lid wiper epitheliopathy (LWE), mucocutaneous junction (Yamaguchi score), and tear osmolarity were not significantly different between the verum and control groups (p > 0.050). We conclude that for most patients with severe DED, 0.15% HMWHA eye drops provide excellent improvement of symptoms without impairment of dry eye signs.

scholarly journals Association between asthma and dry eye disease: a meta-analysis based on observational studies

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e045275
Author(s):  
Qun Huang ◽  
Yanlin Zheng ◽  
Chuantao Zhang ◽  
Wanjie Wang ◽  
Tingting Liao ◽  
...  
Keyword(s):  
Dry Eye ◽  
Subgroup Analysis ◽  
Observational Studies ◽  
Data Extraction ◽  
Meta Analysis ◽  
Population Based ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Control Group ◽  
Increased Risk

ObjectiveThis study aimed to systematically review the relationship between dry eye disease (DED) and asthma based on published population-based studies.Data sourcesPubMed, EMBASE and ISI Web of Science from their inception were searched up to October 2019.Study selectionObservational studies addressing the association between asthma and DED will be eligible.Data extraction and synthesisTwo reviewers independently conducted the data extraction and quality assessment. We used a random-effects model for all analyses. Subgroup analysis according to ethnicity was performed to test the influence of ethnicity on the association.Main outcomes and measuresSix independent studies (a total of 45 215 patients with asthma and 232 864 control subjects) were included in this review and had an average of seven stars by the Newcastle-Ottawa Scale. Our current findings suggest that the prevalence of DED was higher in the asthma group than in the control group (Z=7.42, p<0.00001; OR 1.29, 95% CI 1.20 to 1.38). In the subgroup analysis by ethnicity, Australian, Caucasian and Asian patients with asthma showed an increased risk of DED.

scholarly journals Effect of 0.15% Preservative-free Sodium Hyaluronate on Dry Eye Disease after Femtosecond Laser-assisted Cataract Surgery

2021 ◽  
Vol 62 (7) ◽  
pp. 922-930
Author(s):  
Tae Hwan Kim ◽  
Byunghoon Chung ◽  
Kang Yoon Kim ◽  
Ikhyun Jun ◽  
Kyoung Yul Seo ◽  
...  
Keyword(s):  
Treatment Group ◽  
Dry Eye ◽  
Sodium Hyaluronate ◽  
Tear Film ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Control Group ◽  
Lipid Layer ◽  
Preservative Free

Purpose: The efficacy of using preservative-free 0.15% sodium hyaluronate eyedrops for dry eye disease after femtosecond laser- assisted cataract surgery (FLACS) was evaluated. Methods: This prospective randomized study was conducted on patients with dry eye who were scheduled for FLACS among those with Tear Film & Ocular Surface Society Dry Eye Workshop II Dry Eye Levels 1 and 2. In total, 37 eyes scheduled for FLACS were randomized to the treatment group (n = 19) or control group (n = 18). Corneal and conjunctival fluorescein staining (CFS), tear breakup time (TBUT), Schirmer I test (SIT) value, ocular surface disease index (OSDI), meibomian gland evaluation result, and lipid layer thickness were evaluated for all patients, preoperatively and at 1 and 3 months postoperatively. Results: In the treatment group, the OSDI and CFS scores were significantly lower at 3 months postoperatively than at baseline, but the TBUT and SIT values were significantly increased. In the control group, TBUT was significantly shorter at 3 months postoperatively than at baseline, SIT values were significantly decreased at 1 and 3 months postoperatively compared with the baseline, and meibum quality was significantly aggravated at 1 month postoperatively compared with the baseline. In the treatment group, OSDI improved significantly from baseline at 1 and 3 months. TBUT increased significantly in the treatment group at postoperative 3 months. Meibomian gland quality showed clinically better results in the treatment group than in the control group at postoperative 3 months. There were no significant differences in corneal and CFS, lipid layer thickness, and other dry eye disease parameters between the treatment and control groups. Conclusions: Preservative-free 0.15% sodium hyaluronate eyedrops were effective for improving dry eye symptoms and tear film stability after FLACS.

Sign in / Sign up

Export Citation Format

Share Document